Biogen gears up Swiss manufacturing facility for potential aducanumab rollout

Biogen has had a rocky road with its controversial Alzheimer's disease candidate aducanumab, which it brought back from the dead late last year. But despite postponing the drug's FDA filing by half a year, Biogen is still moving forward with plans to scale up production if aducanumab eventually passes muster.